DGBS e. V. und DGPPN e. V.: S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 1. März 2019 (S3 Leitlinie (Langversion) v2.1) PDF; 8,1 MB), S. 277; 321.
Niels H. Jensen, Ramona M. Rodriguiz, Marc G. Caron, William C. Wetsel, Richard B. Rothman, Bryan L. Roth: N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity. In: Neuropsychopharmacology. Band33, Nr.10, Dezember 2007, S.2303–2312, doi:10.1038/sj.npp.1301646, PMID 18059438.
Katherine Monahan, Jaimie Cuzens-Sutton, Dan Siskind, Steve Kisely: Quetiapine withdrawal: A systematic review. In: The Australian and New Zealand Journal of Psychiatry. Band55, Nr.8, August 2021, S.772–783, doi:10.1177/0004867420965693, PMID 33059460.
C. Rovera, C. M. Esposito, V. Ciappolino, D. Cattaneo, S. Baldelli, E. Clementi, A. C. Altamura, M. Buoli: Quetiapine-Induced Hypomania and its Association with Quetiapine/Norquetiapine Plasma Concentrations: A Case Series of Bipolar Type 2 Patients. In: Drug Safety - Case Reports. Band4, Nr.1, Dezember 2017, S.13n, doi:10.1007/s40800-017-0057-9 (englisch).
R. Bou Khalil, C. Baddoura: Quetiapine Induced Hypomania: A Case Report and a Review of the Literature. In: Current Drug Safety. Vol. 7, Nr.3, 1. September 2012, S.250–253, doi:10.2174/157488612803251333 (amerikanisches Englisch).
espacenet.com
worldwide.espacenet.com
Patent US4879288: Novel dibenzothiazepine antipsychotic. Veröffentlicht am 7. November 1989, Erfinder: Edward J. Warawa, Bernard M. Migler.
fachinfo.de
Fachinfo-Service Beipackzettel für Seroquel (PDF).
go.com
abcnews.go.com
H. Hahn, P. Thomas: Drug Giant AstraZeneca to Pay $520 Million to Settle Fraud Case. In: ABC News. 27. April 2010 (abcnews.go.com).
Howard C. Margolese, Guy Chouinard, Linda Beauclair, Marie-Claire Bélanger: Therapeutic Tolerance and Rebound Psychosis During Quetiapine Maintenance Monotherapy in Patients With Schizophrenia and Schizoaffective Disorder. In: Journal of Clinical Psychopharmacology. Band22, Nr.4, August 2002, S.347 (lww.com [abgerufen am 18. Februar 2024]).
Niels H. Jensen, Ramona M. Rodriguiz, Marc G. Caron, William C. Wetsel, Richard B. Rothman, Bryan L. Roth: N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity. In: Neuropsychopharmacology. Band33, Nr.10, Dezember 2007, S.2303–2312, doi:10.1038/sj.npp.1301646, PMID 18059438.
Katherine Monahan, Jaimie Cuzens-Sutton, Dan Siskind, Steve Kisely: Quetiapine withdrawal: A systematic review. In: The Australian and New Zealand Journal of Psychiatry. Band55, Nr.8, August 2021, S.772–783, doi:10.1177/0004867420965693, PMID 33059460.
M. E. Thase u. a.: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). In: J. Clin. Psychopharmacol. Band 26, 2006, S. 600–609. PMID 17110817.
Ahearn u. a.: Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. In: Int Clin Psychopharmacol. Band 21, Nr. 1, Januar 2006, S. 29–33. PMID 16317314.
